Translation of tissue-engineering innovations requires a connected ecosystem

The potential of tissue engineering to deliver clinical advances hinges on a connected ecosystem that includes academics, funding agencies, entrepreneurs, investors, the pharmaceutical

industry and regulatory bodies. Open dialog on goals and risks across these stakeholders is key to implementing bioengineered tissue models in drug development and tissue therapies. Access

through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal

Receive 12 digital issues and online access to articles $119.00 per year only $9.92 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy

now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer

support REFERENCES * Ingber, D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. _Nat. Rev. Genet._ 23, 467–491 (2022). Article  Google Scholar  *

Vulto, P. & Joore, J. Adoption of organ-on-chip platforms by the pharmaceutical industry. _Nat. Rev. Drug Discov._ 20, 961–962 (2021). Article  Google Scholar  * Proctor, W. R. et al.

Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. _Arch. Toxicol._ 91, 2849–2863 (2017). Article  Google Scholar  * Ewart, L. et al.

Performance assessment and economic analysis of a human liver-chip for predictive toxicology. _Commun. Med._ 2, 154 (2022). Article  Google Scholar  * Peters, M. F. et al. Human 3D

gastrointestinal microtissue barrier function as a predictor of drug-induced diarrhea. _Toxicol. Sci._ 168, 3–17 (2019). Article  Google Scholar  * Fabre, K. et al. Introduction to a

manuscript series on the characterization and use of microphysiological systems (MPS) in pharmaceutical safety and ADME applications. _Lab Chip_ 20, 1049–1057 (2020). Article  Google Scholar

  * Langer, R. & Vacanti, J. P. Tissue Engineering. _Science_ 260, 920–926 (1993). Article  Google Scholar  * Atala, A., Kasper, F. K. & Mikos, A. G. Engineering complex tissues.

_Sci. Transl. Med._ 4, 160rv12 (2012). Article  Google Scholar  * Tollefson, J. The rise of ‘ARPA-everything’ and what it means for science. _Nature_ 595, 483–484 (2021). Article  Google

Scholar  * Higgins, R. F., LaMontagne, S. & Kazan, B. Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: venture philanthropy funding for biotech. _HBS Case Collection_

https://www.hbs.edu/faculty/Pages/item.aspx?num=35037 (October 2007). Download references ACKNOWLEDGEMENTS The authors acknowledge all participants of the Wellcome Leap HOPE-meets-Industry

event (7 December 2022) for the discussion on catalyzing bioengineering innovations. AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Human Organs, Physiology and Engineering (HOPE), Wellcome

Leap, Los Angeles, CA, USA Annie Moisan * Flagship Pioneering, Cambridge, MA, USA David Kolesky * 3D Systems, Houston, TX, USA Jordan Miller * Rice University, Houston, TX, USA Jordan Miller

* Complex in vitro Systems, Safety Assessment, Genentech, South San Francisco, CA, USA Kimberly Homan Authors * Annie Moisan View author publications You can also search for this author

inPubMed Google Scholar * David Kolesky View author publications You can also search for this author inPubMed Google Scholar * Jordan Miller View author publications You can also search for

this author inPubMed Google Scholar * Kimberly Homan View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS All authors contributed to researching

data, discussing content and writing the manuscript. A.M. and K.A.H. reviewed and edited the manuscript for submission and publication. CORRESPONDING AUTHORS Correspondence to Annie Moisan

or Kimberly Homan. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION RELATED LINKS ADVANCED REGENERATIVE MANUFACTURING INSTITUTE:

https://www.armiusa.org/ ADVANCED RESEARCH AND INVENTION AGENCY (ARIA): https://www.aria.org.uk/ ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H): https://arpa-h.gov/ AMERICAN SOCIETY

FOR TESTING AND MATERIALS: https://www.astm.org/ DEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA): https://www.darpa.mil/ EMA STRATEGIC VISION:

https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf EMERGENCY USE AUTHORIZATION:

https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization EUROPEAN ORGAN-ON-CHIP SOCIETY: https://euroocs.eu/ FDA

ALTERNATIVE METHODS WORKING GROUP: https://www.fda.gov/science-research/about-science-research-fda/advancing-alternative-methods-fda FDA MODERNIZATION ACT 2.0:

https://www.nabr.org/about-nabr/news/nabrs-press-statement-fda-modernization-act-20 FEDERAL AGENCY FOR DISRUPTIVE INNOVATIONS (SPRIN-D): https://www.sprind.org/en/ INNOVATIVE SCIENCE AND

TECHNOLOGY APPROACHES FOR NEW DRUGS: https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/innovative-science-and-technology-approaches-new-drugs-istand-pilot-program

INSTITUTE OF HUMAN BIOLOGY: https://institutehumanbiology.com/ IQ MICROPHYSIOLOGICAL SYSTEMS AFFILIATE: https://www.iqmps.org/ INTERNATIONAL MICROPHYSIOLOGICAL SYSTEM SOCIETY:

https://impss.org/ MOONSHOT RESEARCH AND DEVELOPMENT PROGRAM: https://www8.cao.go.jp/cstp/english/moonshot/top.html NATIONAL CENTRE FOR ADVANCING TRANSLATIONAL SCIENCES:

https://ncats.nih.gov/ PARTNERSHIP BETWEEN SEMMA THERAPEUTICS AND THE JUVENILE DIABETES RESEARCH FOUNDATION:

https://t1dfund.org/news/semma-therapeutics-receives-investment-from-jdrf-t1d-fund/ RIGHT TO TRY ACT:

https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try TISSUE CHIP FOR DRUG SCREENING PROGRAM: https://ncats.nih.gov/tissuechip TISSUE CHIP TESTING

CENTERS: https://ncats.nih.gov/tissuechip/projects/centers WELLCOME LEAP: https://wellcomeleap.org/ WELLCOME LEAP HOPE PROGRAM: https://wellcomeleap.org/hope/ RIGHTS AND PERMISSIONS Reprints

and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Moisan, A., Kolesky, D., Miller, J. _et al._ Translation of tissue-engineering innovations requires a connected ecosystem. _Nat Rev

Bioeng_ 1, 879–881 (2023). https://doi.org/10.1038/s44222-023-00111-y Download citation * Published: 04 September 2023 * Issue Date: December 2023 * DOI:

https://doi.org/10.1038/s44222-023-00111-y SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative